TapImmune Inc. Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation Into a Vaccine to Treat HER2/neu Breast Cancer

Published: Apr 16, 2012

SEATTLE, Wash., April 16, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has announced that it has signed an Exclusive Agreement with the Mayo Foundation for Education & Research, Rochester, MN, to License a proprietary MHC Class I HER2/neu antigen technology.

Back to news